Long-term effects of rituximab in rheumatoid arthritis: Clinical, biologic, and pharmacogenetic aspects: Review

Annals of the New York Academy of Sciences

Volumn 1173, Issue , 2009, Pages 692-700

  Quartuccio, Luca ^a   Lombardi, Sandra ^a   Fabris, Martina ^a   Masolini, Paola ^a   Saracco, Marta ^b   Pellerito, Raffaele ^b   De Vita, Salvatore ^a  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b MAURIZIANO HOSPITAL   (Italy)

Author keywords

B cell; Belimumab; Fc receptor; Rheumatoid arthritis; Rituximab

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOGLOBULIN; METHOTREXATE; RITUXIMAB;

AUTOIMMUNE DISEASE; COHORT ANALYSIS; CONFERENCE PAPER; CRYOGLOBULINEMIA; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TREATMENT FAILURE; FOLLOW UP; HEPATITIS C VIRUS; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; LYMPHOCYTE DEPLETION; MEMORY CELL; MONOTHERAPY; OVERALL SURVIVAL; PHARMACOGENETICS; PREDICTION; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE;

EID: 70049095511     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04668.x     Document Type: Conference Paper

References (54)

1. Cohen, S.B., P. Emery, M.W. Greenwald, et al., REFLEX Trial Group. 2006. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54: 2793-2806.
2. Emery, P., R. Fleischmann, A. Filipowicz-Sosnowska, et al., DANCER Study Group. 2006. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54: 1390-1400.
3. Atzeni, F., A. Doria, T. Maurizio & P. Sarzi-Puttini. 2007. What is the role of rituximab in the treatment of rheumatoid arthritis? Autoimmun. Rev. 6: 553-538. Review.
4. Furst, D.E. 2008. The risk of infections with biologic therapies for rheumatoid arthritis. Semin. Arthritis Rheum.; 2008 Dec 29. [Epub ahead of print]. Review.
5. Liossis, S.N. & P.P. Sfikakis. 2008. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin. Immunol. 127: 280-285. Review.
6. Levesque, M.C. & E.W. St Clair. 2008. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J. Allergy Clin. Immunol. 121: 13-21. Review
7. Reff M.E., K. Carner, K.S. Chambers, et al. 1994. Depletion of B cells in vivo by chimeric mouse human monoclonal antibody to CD20. Blood 83: 435-445.
8. Edwards, J.C. & G. Cambridge. 2001. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 40: 205-211.
9. De Vita S., F. Zaja, S. Sacco, et al. 2002. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum. 46: 2029-2033.
10. Fleischmann, R.M., K. Pavelka, A.R. Baldassare, et al. 2005. Preliminary efficacy results of rituximab retreatment in patients with active rheumatoid arthritis. Arthritis Rheum. 52(Suppl 9): S131.
11. Emery, P., R.M. Fleischmann, K. Pavelka, et al. 2005. Safety and tolerability of rituximab retreatment in patients with active rheumatoid arthritis. Arthritis Rheum. 52(Suppl 9): S341.
12. Zaja, F., S. De Vita, C. Mazzaro, et al. 2003. Efficacy and safety of rituximab in type II mixed cryoglobu-linemia. Blood 101: 3827-3834.
13. Quartuccio, L., G. Soardo, G. Romano, et al. 2006. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology 45(7): 842-846.
14. Emery, P., D.E. Furst, G. Ferraccioli, et al. 2007. Sustained efficacy of repeat treatment courses of ritux-imab in rheumatoid arthritis patients with an inadequate response to disease-modifying anti-rheumatic drugs. Ann. Rheum. Dis. 66: S430.
15. Keystone, E., R.M. Fleischmann, P. Emery, et al. 2007. Repeated treatment courses of rituximab in rheumatoid arthritis: sustained efficacy in patients with inadequate response to one or more TNF in hibitors. Ann. Rheum. Dis. 66: S432.
16. van Vollenhoven, R., P. Emery, C. Bingham, et al. 2007. Extended follow-up of long-term safety of rituximab in rheumatoid arthritis. Ann. Rheum. Dis. 66(Suppl II): 88.
17. Keystone E., R. Fleischmann, P. Emery, et al. 2007. Safety and efficacy of additional ourses of rituximab in patients with active rheumatoid arthritis: a open-label extension analysis. Arthritis Rheum. 56: 3896-3908.
18. Genovese, M., P. Emery, E. Ruderman, et al. 2007. Immunoglobulin levels and infection rates in patients with rheumatoid arthritis treated with repeated courses of rituximab. Arthritis Rheum. 56: S149
19. van Vollenhoven, R.F., P. Emery, C.O. Bingham, et al. 2008. Long-term safety of rituximab: 6-year followup of the RA clinical trial and re-treatment popula tion. Arthritis Rheum. 58: S300.
20. Cohen, S., E. Keystone, M. Genovese, et al. 2008. Continued inhibition of structural damage in rheumatoid arthritis patients treated with rituximab at 2 years: REFLEX study. Arthritis Rheum. 58: S303.
21. Popa, C., M.J. Leandro, G. Cambridge, et al. 2007. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 years. Rheumatology 46: 626-630.
22. Dörner T. & G.R. Burmester. 2003. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr. Opin. Rheumatol. 15: 246-252.
23. Takemura, S., P.A. Klimiuk, A. Braun, et al. 2001. T cell activation in rheumatoid synovium is B cell dependent. J. Immunol. 167: 4710-4718.
24. Schroder, A.E., A. Greiner, C. Seyfert, et al. 1996. Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 93: 221-225.
25. Choy, E.H. & G.S. Panayi. 2001. Cytokine pathways ad joint inflammationin rheumatoid arthritis. N. Engl. J. M e d . 344: 907-916.
26. Roll, P., A. Palanichamy, A.S. Rouziere, et al. 2005. B-cell regeneration after B cell depletion with rituximab in patients with rheumatoid arthritis: transient recir-culation of plasmablasts and increased level of germinal center founder cell. Arthritis Rheum. 52(Suppl 9): S289.
27. Leandro, M.J., G. Cambridge, M.R. Eherenstein, et al. 2006. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 54: 613-620.
28. Rouziere, A.S., C. Kneitz, A. Palanichamy, et al. 2005. Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody. Arthritis Res. Ther. 7: R714-R724.
29. Roll, P., T. Dörner & H.P. Tony. 2008. Anti-CD20 therapy in patients with rheumatoid arthritis. Predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum. 58: 1566-1575.
30. Dass S., A.C. Rawstron, E.M. Vital, et al. 2008. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 58: 2993-2999.
31. Thurlings, R.M., K. Vos, C.A. Wijbrandts, et al. 2008. Synovial tissue respons to rituximab: mechanism of action and identification of biomarkers of response. Ann. Rheum. Dis. 67: 917-925.
32. Szodoray, P., P. Alex, V. Dandapani, et al. 2004. Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis. Scand. J. Immunol. 60: 209-218.
33. Edwards, J.C., M.J. Leandro & G. Cambridge. 2004. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum. Dis. Clin. North Am. 30: 393-403.
34. De Vita, S., F. Zaja, S. Sacco, et al. 2002. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum. 46: 2029-2033.
35. Launois, R., S. Payet, N. Saidenberg-Kermanac'h, et al. 2008. Budget impact model of rituximab after failure of one or more TNFalpha inhibitor therapies in the treatment of rheumatoid arthritis. Join Bone Spine; 2008 Oct 23 [Epub ahead of print].
36. La, D.T., C.E. Collins, H.T. Yang, et al. 2008. B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumor necrosis factor alpha antagonists: differential effects between good and poor clinical responders. Ann. Rheum. Dis. 67: 1132-1138.
37. Quartuccio, L., S. Salvin, M. Regis, et al. 2008. Long-term response to rituximab in 36 patients with rheumatoid arthritis: a single centre experience. Ann. Rheum. Dis. 67(Suppl II): 610.
38. Maloney, D.G., B. Smith & A. Rose. 2002. Rituximab: mechanism of action and resistance. Semin. Oncol. 29(1 Suppl 2): 2-9.
39. Uchida J., Y. Hamaguchi, J.A. Oliver, et al. 2004. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199: 1659-1669.
40. Cartron, G., L. Dacheux, G. Salles, et al. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99: 754-758.
41. Hamaguchi, Y., Y. Xiu & K. Komura, et al. 2006. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 203: 743-753.
42. Dall'Ozzo, S. 2004. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 64: 4664-4669.
43. Anolik J.H., D. Campbell, R.E. Felgar, et al. 2003. The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48: 455-459.
44. Cartron, G. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99: 754-758.
45. Tedder, T.F., A. Baras & Y. Xiu. 2006. Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin. Immunopathol. 28: 351-364.
46. Mease, P.J. 2008. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. J. Rheumatol. 35: 1245-1255.
47. Gong, Q., Q. Ou, S. Ye, et al. 2005. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174: 817-826.
48. Mariette, X., S. Roux, J. Zhang, et al. 2003. The level of BLyS (BAFF) correlates with the titre of autoan-tibodies in human Sjögren's syndrome. Ann. Rheum. Dis. 62: 168-171.
49. Petri, M., W. Stohl, W. Chatham, et al. 2008. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 58: 2453-2459.
50. Fabris, M., L. Quartuccio, S. Sacco, et al. 2007. B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection. Rheumatology (Oxford) 46: 37-43.
51. Fabris, M., D. Vicentini, V. De Re, et al. 2007. Elevated B-cell-activating factor of the tumour necrosis factor family in celiac disease. Scand. J. Gastroenterol. 42: 1434-1439.
52. Weller, S., M.C. Braun, B.K. Tan, et al. 2004. Human Blood IgM "memory" B cells are circulating splenic marginal zone B cells harbouring a prediver-sified immunoglobulin repertoire. Blood 104: 3647-3654.
53. McKay, J., H. Chwalinska-Sadowska, E. Boling, et al. 2005. Belimumab (BmAb), a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population. Arthritis Rheum. 52: S710.
54. Cambridge, G., W. Stohl, M.J. Leandro, et al. 2006. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 54: 723-732.